Efficacy and safety of abacavir/lamivudine plus rilpivirine as a first-line regimen in treatment-na ïve HIV-1 infected adults

The anti-retroviral combination of abacavir/lamivudine plus rilpivirine (ABC/3TC/RPV) is not recommended by international guidelines as the first-line regimen. However, it is potent, well-tolerated, and afford...

Source: AIDS Research and Therapy - May 21, 2020 Category: Infectious Diseases Authors: Sharlene Ho, Joshua Guoxian Wong, Oon Tek Ng, Cheng Chuan Lee, Yee Sin Leo, David Chien Boon Lye and Chen Seong Wong Tags: Research Source Type: research